Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Class A Ordinary Shares, par value $0.0001 per share
-
Shares outstanding
-
63.5M
-
Number of holders
-
132
-
Total 13F shares, excl. options
-
37.5M
-
Shares change
-
-21.2M
-
Total reported value, excl. options
-
$268M
-
Value change
-
-$544M
-
Put/Call ratio
-
0.37
-
Number of buys
-
78
-
Number of sells
-
-86
-
Price
-
$7.17
Significant Holders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) as of Q3 2025
216 filings reported holding MLTX - MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share as of Q3 2025.
MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) has 132 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.5M shares
of 63.5M outstanding shares and own 58.99% of the company stock.
Largest 10 shareholders include BVF INC/IL (19.8M shares), Avoro Capital Advisors LLC (2M shares), Cormorant Asset Management, LP (1.99M shares), Balyasny Asset Management L.P. (1.7M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.5M shares), Schonfeld Strategic Advisors LLC (965K shares), PRICE T ROWE ASSOCIATES INC /MD/ (823K shares), FMR LLC (727K shares), Nuveen, LLC (636K shares), and TWO SIGMA INVESTMENTS, LP (454K shares).
This table shows the top 132 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.